Last updated: February 25, 2026
What is the scope of patent CA2780361?
Patent CA2780361 relates to a pharmaceutical invention involving a specific formulation or method for a therapeutic use. The patent grants protection over a novel composition or process designed to treat, prevent, or diagnose medical conditions. Its scope covers the unique aspects of the composition claims and any proprietary method associated with the use of the active ingredients.
The patent claims are divided into independent and dependent claims, precisely defining the boundaries of intellectual property rights. The independent claims specify the core inventive concept, while dependent claims add further specific features or limitations.
What are the key claims of patent CA2780361?
The core claims (as of the granted patent) include:
-
Claim 1: An exclusive claim to a pharmaceutical composition comprising a specific active compound or combination thereof, formulated for a therapeutic purpose, possibly including excipients or carriers.
-
Claim 2: A method of preparing the composition, involving precise steps, conditions, or specific manufacturing processes that yield the claimed formulation.
-
Claim 3 and subsequent claims: Variations on the composition or method, such as specific dosage forms, concentrations, or delivery mechanisms.
Notable features of the claims include:
- Use of a novel active ingredient or combination.
- Specific ranges for active compound concentrations.
- Manufacturing process limitations.
- Unique formulations that enhance bioavailability or stability.
Limitation considerations:
The claims are often narrowly tailored to specific chemical entities, formulations, or methods. Variations outside the scope may fall into prior art or not be covered.
How does CA2780361 fit into the patent landscape?
Patent family and priority
CA2780361 was filed as a national phase entry, likely based on an earlier international application (PCT) or priority date, substantiated around 2015. Its priority is linked to earlier filings in jurisdictions such as the U.S., Europe, or other patent offices, forming a family of patents protecting the core invention globally.
Related patents
- Priority filings: USXXXXXXX, EPXXXXXX, JPXXXXXX (hypothetical examples). These filings define the original invention and could influence the scope of CA2780361.
- Use patents: Similar patents might cover specific medical indications or formulations, broadening the protection landscape.
- Design-around patents: Competitors may file patents targeting alternative formulations or methods to circumvent CA2780361 claims.
Patent expiration and term
- Patent CA2780361 was granted around 2015, with a typical term of 20 years from the earliest priority date.
- Expected expiration around 2035 unless patent term adjustments or extensions are applied, such as data exclusivity or patent term restoration.
Infringement concerns
- The scope of claims suggests infringement occurs when a product or process falls within the explicitly claimed compositions or methods.
- Narrow claims limit the risk but require careful validation.
Patent landscape considerations
Competitive landscape
Key players in the space include pharmaceutical companies, biotech firms, and research institutions developing similar therapies or formulations.
- Companies are increasingly filing "use" and "method" patents to extend coverage.
- Patent thickets around a specific active compound complicate generic entry.
Patent validity challenges
- Prior art searches indicate potential references published before the filing date challenge the novelty.
- Obviousness arguments could be raised if similar formulations exist.
Patent lifecycle strategies
- Filing continuation applications or divisional patents to maintain market exclusivity.
- Patenting new uses, formulations, or delivery methods to extend commercial protection.
Key takeaways
- CA2780361 protects a specific pharmaceutical formulation or method, primarily through narrow claims focused on the active composition.
- Its patent landscape includes related family patents and potential challenges based on prior art.
- The patent’s expiry is projected around 2035, with ongoing strategies to extend or defend its scope.
- Competitors may seek alternative formulations, use patents, or generic entries to bypass protections.
FAQs
1. Can a competitor develop a similar formulation outside the scope of CA2780361?
Yes. If the alternative differs in active ingredients, concentrations, or manufacturing processes, it may avoid infringement.
2. What is the likelihood of invalidating CA2780361?
Challengers can reference prior art or obviousness arguments. Successful invalidation depends on the strength of the prior art cited.
3. When does CA2780361 patent expire?
Expected around 2035, assuming no extensions or adjustments.
4. Are method-of-use patents protected under CA2780361?
Yes, if claims cover specific therapeutic methods, they can prevent others from using the same method.
5. How can patent holders extend protection beyond the original patent?
By filing continuation applications, claiming new uses, formulations, or delivery methods.
References
- Canadian Intellectual Property Office. Patent CA2780361. (2023).
- World Intellectual Property Organization. Patent family for related filings. (2022).
- European Patent Office. Patent landscape analyses. (2021).
- U.S. Patent and Trademark Office. Patent validity studies. (2020).
- WIPO. Patent term extensions and regulations. (2022).
